In the same study, the authors highlighted that insulin therapy, unlike other antidiabetic drugs, was a risk factor for the development of dementia and for equal pathological levels of glycated hemoglobin and other indicators of glycemic unbalance; this result is partially explained by the fact that patients with type 2 diabetes on insulin therapy have a more severe disease, less controlled by first-line drugs, and therefore have a higher risk of comorbidities. The gene discussed is INS; the disease is dementia.